Stocktoria
Ocugen, Inc. OCGN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-12-03
Ocugen, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | $2.5M | $0 |
| R&D expense | $39.8M | $32.1M | $39.6M | — | — |
| Operating income | -$62.9M | -$54.8M | -$65.5M | -$89.1M | -$58.0M |
| Interest expense | — | — | — | — | $79,000 |
| Income tax | $0 | $0 | $0 | $0 | -$52,000 |
| Net income | -$67.8M | -$54.1M | -$63.1M | -$86.8M | -$58.4M |
| EPS (diluted) | — | — | $-0.26 | $-0.40 | $-0.30 |
| Operating cash flow | -$57.0M | -$42.1M | -$62.1M | -$60.1M | -$47.9M |
| Free cash flow | -$57.1M | -$45.5M | -$72.5M | -$64.5M | -$48.9M |
| Cash & equivalents | — | — | $39.5M | $77.6M | $95.0M |
| Total assets | $43.5M | $82.4M | $64.5M | $108.6M | $105.8M |
| Total liabilities | $55.7M | $52.8M | $24.0M | $34.7M | $9.9M |
| Shareholders' equity | -$12.2M | $29.6M | $40.6M | $74.0M | $91.2M |
Source: SEC EDGAR filings · CIK 0001372299 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.